EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization

Jialun Zhang iD, Mingming Du, Lingying Ge iD, Yuheng Cao, Jiang Jiang iD, Xue Yin iD, Guangcun Chen iD, Qiangbin Wang iD

Proceedings of the National Academy of Sciences · 10.11.2026 · 123 (45)

DOI: 10.1073/pnas.2613631123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 04.11.2026. Verfasst von Jialun Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei 230026, China. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Vascular Cell Adhesion Molecule-1, Receptors, Vascular Endothelial Growth Factor. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Strategic Priority Research Program of Chinese Academy of Sciences, the National Key Research and Development Program, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wet age-related macular degeneration (AMD), a leading cause of irreversible vision loss, is driven by pathological choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor (anti-VEGF) therapies remain the clinical standard, their utility is constrained by incomplete responses in nearly 50% of patients and off-target risks—such as geographic atrophy—stemming from non-specific VEGF blockade. Here, we identify a robust correlation between vascular cell adhesion molecule-1 (VCAM-1) and VEGF/VEGF receptor (VEGFR) expression in aqueous humor from AMD patients and in murine CNV models. Thus, we engineered a tetravalent bispecific protein, RHV, by functionalizing an L-rhamnulose-1-phosphate aldolase scaffold with peptides that selectively bind VCAM-1 and the VEGFR on neovessels. The tetravalent design confers high apparent affinity, enhancing pathological endothelial targeting while sparing healthy retinal vasculature. RHV induces concurrent internalization and lysosomal degradation of both VCAM-1 and VEGFR via a head-to-tail binding mode, leading to sustained inhibition of the VEGF/VEGFR, PI3K/AKT and Apelin/APJ signaling pathways. In murine CNV models, a single intravitreal injection of RHV exhibits superior ocular retention and lesion penetration, achieving therapeutic efficacy comparable to aflibercept [a ligand-trap fusion protein for VEGF-A, VEGF-B and placental growth factor (PIGF)] at one-quarter of the molar dose. This dual-receptor degradation-based strategy represents a targeted and durable approach for treating ocular neovascularization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Choroidal NeovascularizationVascular Cell Adhesion Molecule-1Receptors, Vascular Endothelial Growth FactorAnimalsHumansMiceProteolysisMacular DegenerationDisease Models, AnimalMice, Inbred C57BLVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

age-related macular degenerationchoroidal neovascularizationdual-targeted protein degradationtetravalent proteinvascular cell adhesion molecule-1

Substanzen

Vascular Cell Adhesion Molecule-1Receptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • School of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei 230026, China.
  • Key Laboratory of Nano-Bio Interface, Jiangsu Key Laboratory of Organoid Engineering and Precision Medicine, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Scie…
  • Department of Ophthalmology, The First Affiliated Hospital of Soochow University, Suzhou 21006, China.
  • School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Global Institute of Future Technology, Shanghai Jiao Tong University, Shanghai 200240, China.

ORCID-Profile: Jialun Zhang, Lingying Ge, Jiang Jiang, Xue Yin, Guangcun Chen, Qiangbin Wang

Förderung

  • the Strategic Priority Research Program of Chinese Academy of Sciences
  • the National Key Research and Development Program
  • the National Natural Science Foundation of China
  • the Basic Research Program of Jiangsu
  • the Science and Technology Project of Suzhou
  • the Suzhou Basic Research Pilot Project

Zitieren

APA

Zhang, J., Du, M., Ge, L., Cao, Y., Jiang, J., Yin, X., Chen, G., & Wang, Q. (2026). A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization. Proceedings of the National Academy of Sciences, 123(45). https://doi.org/10.1073/pnas.2613631123

Vancouver

Zhang J, Du M, Ge L, Cao Y, Jiang J, Yin X, et al. A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization. Proceedings of the National Academy of Sciences. 2026;123(45). doi:10.1073/pnas.2613631123

BibTeX
@article{Zhang2026,
  author = {Zhang, Jialun and Du, Mingming and Ge, Lingying and Cao, Yuheng and Jiang, Jiang and Yin, Xue and Chen, Guangcun and Wang, Qiangbin},
  title = {A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {45},
  doi = {10.1073/pnas.2613631123}
}
Kostenlos starten →